Core Viewpoint - Genting New Year (01952) has announced a subscription for 15.8462 million American Depositary Shares (ADS) of I-Mab at a price of $1.95 per ADS, totaling approximately $30.9 million, which will result in a 16.1% ownership stake in I-Mab post-transaction [1][2] Group 1 - Genting New Year shares rose over 3% and were trading at HKD 63.5 with a transaction volume of HKD 147 million at the time of reporting [1] - The subscription price of $1.95 per ADS is equivalent to approximately HKD 15.3 per ADS [1] - The total consideration for the subscription amounts to approximately HKD 243 million [1] Group 2 - I-Mab is a global biotechnology company based in the United States, focusing on developing precision immuno-oncology drugs for cancer treatment [1] - I-Mab currently has three clinical-stage pipeline products: Givastomig, Ragistomig, and Uliledlimab [1] - The board believes that the subscription will confirm I-Mab's unique capabilities in clinical translation, particularly in the U.S., and will complement Genting New Year's strong influence in Asia [2]

据介绍，I-Mab为一间总部设于美国的全球性生物科技公司，专注于研发针对癌症治疗的精准免疫肿瘤 学药物。I-Mab目前有三项处于临床阶段的管线产品，包括Givastomig(Claudin 18.2 x 4-1BB双特异性抗 体)、Ragistomig(PD-L1 x 4-1BB双特异性抗体)及Uliledlimab(CD73抗体)。 消息面上，云顶新耀发布公告，于2025年8月1日，本公司认购I-Mab(I-Mab)(一间于纳斯达克全球市场上 市的公司，股份代号为"IMAB")的1584.62万股美国预托股份(ADS)(每10股ADS相当于23股普通股)(认购 事项)，每股ADS为1.95美元(相当于约每股ADS15.3港元)。认购事项的总代价为3090万美元(相当于约 2.43亿港元)。认购事项完成后，本公司将合共持有1584.62万股ADS及607.86万股普通股，占紧随认购 事项结束后经配发及发行ADS扩大后I-Mab已发行股本总额约16.1%。 智通财经APP获悉，云顶新耀(01952)涨超3%，截至发稿，涨2.25%，报63.5港元，成交额1.47亿港元。 董事会认为，认购事项可确认I-Mab于临 ...